About us

World pioneers in the implementation of Personalised Medicine.

International Centre for Neuroscience and Genomic Medicine

The EuroEspes International Centre for Neuroscience and Genomic Medicine bases its activity on cutting-edge Personalised Medicine using all the diagnostic and therapeutic resources provided by structural and functional genomics, epigenetics, transcriptomics, proteomics, and metabolomics.

EuroEspes is an International Centre of Reference in Genomic Medicine, dedicated above all to diseases of the nervous system and other prevalent diseases (cardiovascular diseases, cancer, metabolic disorders, and any genetic-based pathology).

The three major pathologies that account for 80% of morbidity and mortality in developed countries are cardiovascular diseases ( 25-35%), cancer (20-30%) and brain disorders (10-20%). 80-90% of these prevalent diseases have a multifactorial pathogenesis in which genomic factors and environmental factors converge. Although these diseases can occur at any age, in more than 70% of cases they are age-dependent pathologies, which accumulate with age, increasing their prevalence in adulthood and old age. Consequently, they are diseases that develop throughout life and, therefore, are predictable with the appropriate predictive procedures, and susceptible to prevention, since when they appear they have already been undermining our body for decades.


One of the priorities of the International Centre for Neuroscience and Genomic Medicine is the implementation of Prevention Plans for prevalent diseases to identify them in pre-symptomatic or early stages and to be able to intervene prophylactically so that they do not manifest themselves, delay their onset or can be intervened therapeutically in an effective way with personalised protocols of individual pharmacogenetics.

The EuroEspes International Centre for Neuroscience and Genomic Medicine is a world pioneer in the implementation of a Personalised Medicine based on the knowledge of the Human Genome. EuroEspes makes predictive medicine available to society, which allows us to be one step ahead of prevention and which will become the medicine of the future in the coming years.

We are the first private company dedicated exclusively to the research, diagnosis, and treatment of diseases of the Central Nervous System. Based in Bergondo (A Coruña), EuroEspes is an international benchmark and leader in Spain in this field of activity, with pioneering patents on nutraceutical bioproducts and pharmacogenomics.

EuroEspespes has been listed in the BME Growth.(Spanish Alternative Stock Market) since 2011 (this stock market was known as MAB until September 2020).

Our team is made up of healthcare and research personnel with extensive international experience in Japan, the United States, the United Kingdom, and India, which, together with state-of-the-art technological equipment, allows us to offer an optimal level in the organisation and development of the different medical, healthcare, teaching and research activitieswe carry out. We have been involved in:

  • more than 150 research projects
  • more than 2000 scientific publications

Euroespes Group

The EuroEspes Group, made up of the EuroEspes International Center for Neuroscience and Genomic Medicine, EuroEspes Biotechnology and EuroEspes Publishing, represents an international benchmark in research, implementation and dissemination of the most innovative advances in Genomic and Personalised Medicine, as well as in Health Biotechnology and the development of Therapeutic Bioproducts.

We have more than 30 years of experience in Genomic Medicine and Biotechnology Research.

Recognition and awards

Euroespes Supplement Award
Euroespes Economic News Prize
Economic News Prize pharmacogenetics card
Cantabrian Euroespes Excellent Cantabrian Award

Leave us your contact information and we will contact you.

Leave us your contact information and we will contact you.